sabato, 4 dicembre 2021
4 Luglio 2019

FDA approves new treatment for refractory multiple myeloma

July 3, 2019 – Today, the U.S. Food and Drug Administration granted accelerated approval to selinexor tablets in combination with the corticosteroid dexamethasone for the treatment of adult patients with relapsed refractory multiple myeloma (RRMM) who have received at least four prior therapies and whose disease is resistant to several other forms of treatment, including at least two proteasome inhibitors, at least two immunomodulatory agents, and an anti-CD38 monoclonal … (leggi tutto)